These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 27398637)

  • 1. Ocular surface toxicity from glaucoma topical medications and associated preservatives such as benzalkonium chloride (BAK).
    Aguayo Bonniard A; Yeung JY; Chan CC; Birt CM
    Expert Opin Drug Metab Toxicol; 2016 Nov; 12(11):1279-1289. PubMed ID: 27398637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells.
    Ammar DA; Noecker RJ; Kahook MY
    Adv Ther; 2010 Nov; 27(11):837-45. PubMed ID: 20931366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of benzalkonium chloride- and polyquad-preserved combination glaucoma medications on cultured human ocular surface cells.
    Ammar DA; Noecker RJ; Kahook MY
    Adv Ther; 2011 Jun; 28(6):501-10. PubMed ID: 21603985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preservative toxicity in glaucoma medication: clinical evaluation of benzalkonium chloride-free 0.5% timolol eye drops.
    Rosin LM; Bell NP
    Clin Ophthalmol; 2013; 7():2131-5. PubMed ID: 24204115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preservatives in glaucoma medication.
    Steven DW; Alaghband P; Lim KS
    Br J Ophthalmol; 2018 Nov; 102(11):1497-1503. PubMed ID: 29973365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tear Film, Conjunctival and Corneal Modifications Induced by Glaucoma Treatment.
    Roberti G; Tanga L; Manni G; Riva I; Verticchio AC; Berardo F; Carnevale C; Oddone F
    Curr Med Chem; 2019; 26(22):4253-4261. PubMed ID: 31099319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ocular Surface Disease in Glaucoma: Effect of Polypharmacy and Preservatives.
    Ramli N; Supramaniam G; Samsudin A; Juana A; Zahari M; Choo MM
    Optom Vis Sci; 2015 Sep; 92(9):e222-6. PubMed ID: 25730335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears.
    Kahook MY; Noecker RJ
    Cornea; 2008 Apr; 27(3):339-43. PubMed ID: 18362664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic Effects of Sodium Hyaluronate on Ocular Surface Damage Induced by Benzalkonium Chloride Preserved Anti-glaucoma Medications.
    Liu X; Yu FF; Zhong YM; Guo XX; Mao Z
    Chin Med J (Engl); 2015 Sep; 128(18):2444-9. PubMed ID: 26365960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ocular benzalkonium chloride exposure: problems and solutions.
    Goldstein MH; Silva FQ; Blender N; Tran T; Vantipalli S
    Eye (Lond); 2022 Feb; 36(2):361-368. PubMed ID: 34262161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benzalkonium chloride and glaucoma.
    Rasmussen CA; Kaufman PL; Kiland JA
    J Ocul Pharmacol Ther; 2014; 30(2-3):163-9. PubMed ID: 24205938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Restoring conjunctival tolerance by topical nuclear factor-κB inhibitors reduces preservative-facilitated allergic conjunctivitis in mice.
    Guzmán M; Sabbione F; Gabelloni ML; Vanzulli S; Trevani AS; Giordano MN; Galletti JG
    Invest Ophthalmol Vis Sci; 2014 Sep; 55(9):6116-26. PubMed ID: 25190648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Glaucoma medications, preservatives and the ocular surface.].
    Aptel F; Labbé A; Baudouin C; Bron A; Lachkar Y; Sellem E; Renard JP; Nordmann JP; Rouland JF; Denis P
    J Fr Ophtalmol; 2014 Nov; 37(9):728-736. PubMed ID: 25440185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the ocular surface changes following the use of two different prostaglandin F2α analogues containing benzalkonium chloride or polyquad in rabbit eyes.
    Lee HJ; Jun RM; Cho MS; Choi KR
    Cutan Ocul Toxicol; 2015; 34(3):195-202. PubMed ID: 25265260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical audit examining the impact of benzalkonium chloride-free anti-glaucoma medications on patients with symptoms of ocular surface disease.
    Goldberg I; Graham SL; Crowston JG; d'Mellow G;
    Clin Exp Ophthalmol; 2015 Apr; 43(3):214-20. PubMed ID: 25196488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sodium hyaluronate decreases ocular surface toxicity induced by benzalkonium chloride-preserved latanoprost: an in vivo study.
    Yu F; Liu X; Zhong Y; Guo X; Li M; Mao Z; Xiao H; Yang S
    Invest Ophthalmol Vis Sci; 2013 May; 54(5):3385-93. PubMed ID: 23620425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Corneal sensitivity in patients treated medically for glaucoma or ocular hypertension].
    Van Went C; Alalwani H; Brasnu E; Pham J; Hamard P; Baudouin C; Labbé A
    J Fr Ophtalmol; 2011 Dec; 34(10):684-90. PubMed ID: 22093372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of topical intraocular pressure lowering medications on the ocular surface of glaucoma patients: A review.
    Asiedu K; Abu SL
    J Curr Ophthalmol; 2019 Mar; 31(1):8-15. PubMed ID: 30899840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benzalkonium chloride in glaucoma medications.
    Noecker R; Miller KV
    Ocul Surf; 2011 Jul; 9(3):159-62. PubMed ID: 21791190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Controversy: Is Benzalkonium Chloride Necessary in Antiglaucoma Drops?
    Louati Y; Shaarawy T
    J Curr Glaucoma Pract; 2012; 6(3):104-7. PubMed ID: 26997764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.